There were 674 press releases posted in the last 24 hours and 150,792 in the last 365 days.

Trevena Losses Alert: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Trevena, Inc. – TRVN

NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) between May 2, 2016 and October 8, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover Trevena shareholders’ investment losses.

If you purchased Trevena securities, and/or would like to discuss your legal rights and options, please visit Trevena Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

According to the lawsuit Trevena misled its shareholders to believe that its April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration (“FDA”) was far more successful than it actually was. The Company did so by issuing a press release entitled “Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine,” on May 2, 2016, in which it announced that it had “reached general agreement” with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was “very pleased” with the outcome of its discussions with the FDA. 

However, in fact, on October 9, 2018, minutes from the FDA’s April 28, 2016 meeting with Trevena were released and showed that the FDA:

  • “did not agree with the proposed dosing in the Phase 3 studies”;
  • “did not agree with the proposed primary endpoint”; and
  • “did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine.”

On this news, Trevena stock fell $2.04 per share, or over 68%, over the next two trading days to close at $0.947 per share on October 10, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than December 10, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Trevena securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/trevena-inc-trvn-lawsuit-class-action-fraud-stock-88/ or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
dsadeh@bernlieb.com

/EIN News/ --

BL-new-logo.jpg

Distribution channels: Law, Technology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.